推薦產品
生化／生理作用
JNJ-55511118 is also known as 5-[2-chloro-6-(trifluoromethoxy)phenyl]-1,3-dihydrobenzimidazol-2-one. It acts as an anticonvulsant or neuroprotectant. It is considered as a reversible α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor inhibitor, mainly in the hippocampus region.
JNJ-55511118 is an orally available, brain penetrant, potent and selective negative modulator of AMPA receptors that requires the presence of the accessory protein CACNG8 (TARP-γ8). JNJ-55511118 exhibit potent inhibition of neurotransmission within hippocampus, and a strong anti-convulsant effect.
訊號詞
Warning
危險聲明
危險分類
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
標靶器官
Respiratory system
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Michael P Maher et al.
The Journal of pharmacology and experimental therapeutics, 357(2), 394-414 (2016-03-19)
Members of the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid (AMPA) subtype of ionotropic glutamate receptors mediate the majority of fast synaptic transmission within the mammalian brain and spinal cord, representing attractive targets for therapeutic intervention. Here, we describe novel AMPA receptor modulators that require
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務